Serina Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except par value amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,056 | $3,672 |
| Prepaid expenses and other current assets | 3,024 | 2,004 |
| Total current assets | 6,080 | 5,676 |
| Property and equipment, net | 465 | 501 |
| Right of use assets - operating leases | 377 | 461 |
| Right of use assets - finance leases | — | 86 |
| Other long-term prepaid assets | 29 | — |
| TOTAL ASSETS | $6,951 | $6,724 |
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,931 | $744 |
| Accrued expenses | 1,207 | 1,429 |
| Warrant liability | 88 | — |
| Other current liabilities | 337 | 193 |
| Total current liabilities | 3,563 | 2,366 |
| Warrant liability, non-current | 283 | 3,582 |
| Convertible Note, net | 2,946 | — |
| Operating lease liabilities, net of current portion | 196 | 268 |
| TOTAL LIABILITIES | 6,988 | 6,216 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ (deficit) equity: | ||
| Series A convertible preferred stock, $0.0001 par value, 5,000 shares authorized; 965 and zero shares issued and outstanding at December 31, 2025 and 2024, respectively; liquidation preference of $5,000 and zero at December 31, 2025 and 2024, respectively; | 4,940 | — |
| Common stock, $0.0001 par value, 40,000 shares authorized; and 10,767 and 9,422 shares issued and outstanding at December 31, 2025 and 2024, respectively; (including 57 shares declared as a stock dividend on April 1, 2025 and issued on March 31, 2026) | 1 | 1 |
| Additional paid-in capital | 58,536 | 44,958 |
| Accumulated other comprehensive loss | (14) | — |
| Accumulated deficit | (63,500) | (44,318) |
| Total Serina Therapeutics, Inc. stockholders’ (deficit) equity | (37) | 641 |
| Noncontrolling deficit | — | (133) |
| TOTAL STOCKHOLDERS' (DEFICIT) EQUITY | (37) | 508 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $6,951 | $6,724 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.